Niederst, Matthew J.
Sequist, Lecia V.
Poirier, John T.
Mermel, Craig H.
Lockerman, Elizabeth L.
Garcia, Angel R.
Katayama, Ryohei
Costa, Carlotta
Ross, Kenneth N.
Moran, Teresa
Howe, Emily
Fulton, Linnea E.
Mulvey, Hillary E.
Bernardo, Lindsay A.
Mohamoud, Farhiya
Miyoshi, Norikatsu
VanderLaan, Paul A.
Costa, Daniel B.
Jänne, Pasi A.
Borger, Darrell R.
Ramaswamy, Sridhar
Shioda, Toshi
Iafrate, Anthony J.
Getz, Gad
Rudin, Charles M.
Mino-Kenudson, Mari
Engelman, Jeffrey A.
Article History
Received: 27 April 2014
Accepted: 21 January 2015
First Online: 11 March 2015
Competing interests
: J.A.E. is a consultant for Novartis, Sanofi-Aventis, Genentech and Astra Zeneca; owns equity in Gatekeeper Pharmaceuticals, which has interest in T790M inhibitors; is a Scientific Advisory Board member for Sanofi-Aventis; has research agreements with Novartis, Sanofi-Aventis and Astra Zeneca. A.J.I. is a consultant for Pfizer and Bioreference Laboratories. P.A.J. is a consultant for AstraZeneca, Boehringer Ingelheim, Chugai Pharma, Clovis, Genentech, Merrimack Pharmaceuticals, Pfizer and Sanofi; owns stock in Gatekeeper Pharmaceutical; receives other renumeration from LabCorp. C.M.R. has been a recent consultant for AbbVie, Biodesix, Boehringer Ingelheim, Glaxo Smith Kline and Merck regarding cancer drug development. The remaining authors declare no competing financial interests.